Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 17, No. 2, 2010
Issue release date: January 2010
Section title: Original Paper
Free Access
Neuroimmunomodulation 2010;17:120–125

Expression of Activity-Dependent Neuroprotective Protein in the Immune System: Possible Functions and Relevance to Multiple Sclerosis

Braitch M.a · Kawabe K.a · Nyirenda M.a · Gilles L.J.a · Robins R.A.b · Gran B.a · Murphy S.c · Showe L.d · Constantinescu C.S.a
aDivision ofClinical Neurology, School of Clinical Sciences, bDivision of Immunology, School of Molecular Medical Sciences, Medical School, Queens Medical Centre, Nottingham University, Nottingham, UK; cDepartment of Neurological Surgery, University of Washington, Seattle, Wash., and dSystemsBiology Division, Genomics Core, The Wistar Institute, Philadelphia, Pa., USA
email Corresponding Author

Prof. Cris S. Constantinescu

Division of Clinical Neurology, Medical School, B Floor

Queens Medical Centre, Nottingham University, Nottingham NG7 2UH (UK)

Tel. +44 115 875 4597, Fax +44 115 970 9738

E-Mail cris.constantinescu@nottingham.ac.uk


  1. Zusev M, Gozes I: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004;123:33–41.
  2. Li H, Mei Y, Wang Y, Xu L: Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006;26:430–437.
  3. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, Delgado M: Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 2006;168:1179–1188.
  4. Gozes I: Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther 2007;114:146–154.
  5. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I: Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001;276:708–714.
  6. Gozes I, Divinski I: The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J Alzheimers Dis 2004;6:S37–S41.
  7. Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D: NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann NY Acad Sci 2006;1070:500–506.
  8. Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE: A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann NY Acad Sci 2000;921:115–118.
  9. Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE: A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann NY Acad Sci 1999;897:125–135.
  10. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM: The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005;2:149–153.
  11. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CFD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971–979.
  12. Kierdorf K, Wang Y, Neumann H: Immune-mediated CNS damage. Results Probl Cell Differ 2009.
  13. Kosmaczewska A, Bilinska M, Ciszak L, Noga L, Pawlak E, Szteblich A, Podemski R, Frydecka I: Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). J Neuroimmunol 2007;189:137–146.
  14. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL: Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599–603.
  15. Segal BM: The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol 2007;191:2–7.
  16. Martino G, Grohovaz F, Brambilla E, Codazzi F, Consiglio A, Clementi E, Filippi M, Comi G, Grimaldi LM: Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann Neurol 1998;43:340–349.
  17. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097–1102.
  18. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H: The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175–1189.